Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs.

Arthritis research & therapy - 1 Jan 2006

López Patricia, Gómez Jesús, Mozo Lourdes, Gutiérrez Carmen, Suárez Ana

Abstract excerpt

Antimalarial agents have been widely used as disease-modifying antirheumatic drugs in the treatment of systemic lupus erythematosus (SLE) and other rheumatological diseases, although their mechanism of action has not yet been fully defined. It is known, however, that effective response to treatment is variable among patients. Thus, the identification of genetic predictors of treatment response would provide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimalarials
Share to Case-Control Studies
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-10

Share to Lupus Erythematosus, Systemic

Share to Polymorphism, Genetic

Share to Treatment Outcome

Share to Tumor Necrosis Factor-alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 16507146
DOI: 10.1186/ar1897
PMCID: PMC1526590

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs.PMID 16507146Read ↗

Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment.Semantic proximity Read ↗

Cytokine gene polymorphisms in Colombian patients with systemic lupus erythematosus.Semantic proximity Read ↗

The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.Semantic proximity Read ↗

Tumor necrosis factor alpha promoter polymorphism -308 G/A in Brazilian patients with systemic lupus erythematosus.Semantic proximity Read ↗

Pharmacogenetics in treatment of rheumatoid arthritis.Semantic proximity Read ↗

Association of interleukin-10 promoter haplotypes with disease susceptibility and IL-10 levels in Mexican patients with systemic lupus erythematosus.Semantic proximity Read ↗

Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response.Semantic proximity Read ↗

Putative IL-10 Low Producer Genotypes Are Associated with a Favourable Etanercept Response in Patients with Rheumatoid Arthritis.Semantic proximity Read ↗

IL-10 and TNFalpha genotypes in SLE.Semantic proximity Read ↗

TNF-α promoter polymorphisms (G-238A and G-308A) are associated with susceptibility to Systemic Lupus Erythematosus (SLE) and P. falciparum malaria: a study in malaria endemic areaSemantic proximity Read ↗

Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy.Semantic proximity Read ↗

Interferon gamma and Interleukin 10 polymorphisms in Brazilian patients with systemic lupus erythematosus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.